Synapse - Eileen O'Reilly

Results (790)

Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: Sensitivity analysis of survival from the NAPOLI 3 trial

Meeting Abstract

Wainberg, Z.; Melisi, D.; Macarulla, T.; Cid, R. P.; Chandana, S.; de la Fouchardiere, C.; Dean, A.; Kiss, I.; Lee, W.; Goetze, T.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Outcomes in advanced hepatocellular carcinoma (HCC) patients (pts) treated with immune checkpoint inhibitors (ICI)

Meeting Abstract

Cowzer, D.; Capanu, M.; Keane, F.; Khalil, D.; Shia, J.; Do, R.; Chou, J.; Walch, H.; El Dika, I.; Yaqubie, A.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Patients (pts) with advanced hepatocellular carcinoma (HCC) with long-term response to immune checkpoint inhibitor (ICI) therapy

Meeting Abstract

Keane, F.; Cowzer, D.; Khalil, D.; Shia, J.; Do, R.; Folorunso, S.; El Dika, I.; Yaqubie, A.; Kim, T.; O'Reilly, E.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

NALIRIFOX (iposomal irinotecan + 5-fluorouracil/feucovorin + oxaliplatin) versus FOLFOX [5-fluorouracil/leucovorin + oxaliplatin] as first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): Real-world comparative overall survival

Meeting Abstract

O'Reilly, E.; Li, J.; DerSarkissian, M.; Chang, R.; Cheng, M.; Yu, L.; Rane, D.; Zhang, L.; Xiao, Z.; Benzaghou, F.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Preoperative treatment of locally advanced rectal cancer

Journal Article

Schrag, D.; Qian, S.; Weiser, M. R.; Gollub, M. J.; Saltz, L. B.; Musher, B. L.; Goldberg, J.; Al Baghdadi, T.; Goodman, K. A.; McWilliams, R. R.; more...
New England Journal of Medicine (2023)

Fulltext@MSK | Save

Alliance A022101: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer – Evaluating radiation, ablation and surgery (ERASur)

Meeting Abstract

Romesser, P. B.; Miller, E. D.; Shi, Q.; Dixon, J. G.; Gholami, S.; White, S.; Wu, C.; Goulet, C. C.; Jee, K. W.; Wright, C. L.; more...
International Journal of Radiation Oncology, Biology, Physics (2023)

Fulltext@MSK | Save

Patient-reported adverse events during neoadjuvant therapy in a phase 2 borderline resectable pancreatic cancer clinical trial (Alliance A021501)

Conference Paper

Snyder, R. A.; Dueck, A. C.; Fruth, B.; Shi, Q.; Hubbard, J. M.; Herman, J. M.; O'Reilly, E. M.; Katz, M. H. G.
Lippincott Williams & Wilkins (2023)

Fulltext@MSK | Save

Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma

Meeting Abstract

Del Rivero, J.; Perez, K.; Geyer, S. M.; Khalil, M. F.; Vijendran, A.; Kordaris-Corkill, A.; Shergill, A.; Spencer, K. R.; Soares, H. P.; Lopez, C. D.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA 1/2+) pathogenic variants: SWOG S2001

Meeting Abstract

Chung, V.; Guthrie, K. A.; Pishvaian, M. J.; Reiss, K. A.; Lowy, A. M.; Sohal, D.; Colby, S.; Sharon, E.; Allegra, C. J.; O'Reilly, E. M.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

A phase 1b, open-label, two-part safety, tolerability, and efficacy study of a soluble beta-glucan (odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma whose disease did not progress during first-line (1L) chemotherapy

Meeting Abstract

O'Hara, M. H.; Wattenberg, M. M.; Garrido-Laguna, I.; O'Reilly, E. M.; Yellin, M. J.; Keler, T.; Gargano, M. A.; Niles, N.; Drees, J.; Bose, N.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save